Results analysis from Kepler Trust Intelligence

Summary by AI BETAClose X

International Biotechnology Trust (IBT) reported strong half-year results with NAV total returns of 35.7%, outperforming the Nasdaq Biotechnology Index's 29.5% return, and share price total returns of 39% as the discount narrowed to 6.7%. M&A activity was a significant driver, with five portfolio companies acquired, and this trend has continued with five more acquisitions by April 29, 2026, all at a premium. Key performance contributors included positive news for uniQure, Vera Therapeutics, and Terns Pharmaceutical, with management's trading decisions notably benefiting from uniQure's gains. The trust remains focused on late-stage and commercialized companies, seeking attractive valuations and acquisition potential.

Disclaimer*

UK 100

Latest directors dealings